# A Study to Evaluate the Effect of Sarpogrelate on Blood Hyperviscosity

> **NCT03509922** · PHASE4 · COMPLETED · sponsor: **Yuhan Corporation** · enrollment: 60 (actual)

## Conditions studied

- Peripheral Artery Disease, PAD

## Interventions

- **DRUG:** Anplag Tab. 100mg bid
- **DRUG:** Anplag Tab. 100mg tid

## Key facts

- **NCT ID:** NCT03509922
- **Lead sponsor:** Yuhan Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-11
- **Primary completion:** 2019-12-26
- **Final completion:** 2020-03-05
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2020-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03509922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03509922, "A Study to Evaluate the Effect of Sarpogrelate on Blood Hyperviscosity". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03509922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*